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Placental site trophoblastic tumor (PSTT) is a very rare
and unique form of gestational trophoblastic disease
(GTD). This tumor represents a neoplastic transforma-
tion of intermediate trophoblastic cells that normally
play a critical role in implantation. PSTT can occur after
a normal pregnancy, abortion, term delivery, ectopic
pregnancy or molar pregnancy. Here we report a case
of PSTT which was incidentally detected in the endome-
trial curetting of a 45-year-old woman and later con-
firmed on microscopic examination of the hysterectomy
specimen.
A 45-year-old woman presented to the Department
of Gynecology with the complaint of menorrhagia of 
6 months’ duration. Her past history included a spon-
taneous abortion 8 years before. Ultrasonography
revealed multiple fibroids in the uterus. Speculum ex-
amination showed an endocervical cyst, which was
excised; it was sent, along with specimen of endometrial
curettings, for histopathological examination. Micro-
scopy revealed multiple fragments of endometrium
showing proliferative phase, as well as some fragments
with invading tumor cells in nests and cords, separat-
ing myometrial muscle fibers, both individually and in
groups (Figure 1). These tumor cells were large and poly-
gonal with irregular vesicular nuclei and prominent
nucleoli, and showed abundant dense eosinophilic 
to amphophilic cytoplasm with occasional vacuoles.
Abundant extracellular fibrinoid material was seen
around tumor nests (Figure 2). Tumor cells showed
characteristic vascular invasions, replacing vessel walls
(Figure 3). There were occasional mitotic figures (0–1/
10 high power field). Possibility of PSTT was suggested.
Serum beta human chorionic gonadotropin (β-hCG)
level was within normal limits. The patient underwent
hysterectomy and bilateral salphingo-oophorectomy.
On gross examination, hysterectomy specimen re-
vealed a growth measuring 2 × 1.5 × 1 cm in the lower
uterine segment, just above the endocervical canal
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Figure 1. Fragments showing nests and cords of tumor cells
infiltrating myometrium along with fragments of endometrium
(hematoxylin and eosin stain, 100×).
Figure 2. Higher magnification revealing sheets of intermedi-
ate trophoblasts replacing the wall of uterine blood vessel
(hematoxylin and eosin stain, 200×).
(Figure 4). The growth was gray-white in cut section and
invaded the myometrium. In addition, there were mul-
tiple intramural and subserosal fibroids. Microscopic
examination of the growth revealed similar features as
the endometrial curettings, with invasion of more than
half of the myometrium, confirming the initial diagno-
sis of PSTT.
PSTT is a rare form of GTD that originates from the
implantation site of an intermediate trophoblast. It
accounts for about 1% of all GTDs, with an estimated
incidence of 1 per 100,000 pregnancies [1]. This clini-
cal and pathological entity was first described in 1976
by Kurman et al [2], when the term “trophoblastic
pseudotumor” was used to describe a disease follow-
ing a benign clinical course. It soon became apparent
that those cases in the original report were not wholly
representative of the disease spectrum and that this
tumor did indeed have a malignant potential [3], leading
to the current nomenclature [4].
PSTT is a rare neoplastic proliferation of extravillous
intermediate trophoblasts at the implantation site. It
belongs to an extraordinary group of neoplasms that
are fetal in origin and associated with infiltration of the
maternal endometrium and myometrium. It is seen in
patients 19–62 years, with an average age of 30 years,
and can present with either amenorrhea or abnormal
bleeding, often accompanied by uterine enlargement
[5]. It can occur after a normal pregnancy, spontaneous
abortion, termination of pregnancy, ectopic pregnancy
or molar pregnancy [6].
β-hCG is a tumor marker used in evaluating treat-
ment and follow-up of patients with choriocarcinoma
and molar pregnancies, in which the β-hCG level cor-
relates with tumor bulk and persistence of disease.
This is not true of PSTT; rather, a low β-hCG estimation
in patients with a relatively large tumor burden should
elicit clinical suspicion of a PSTT. The low levels of 
β-hCG produced by PSTT reflects the cellular origin of
this tumor type: intermediate trophoblast cells produce
little β-hCG and larger quantities of human placental
lactogen (hPL) [7]. The serum levels of β-hCG are usually
in the range of 1,000–2,000 mIU/mL. The usual im-
munohistochemical staining pattern for PSTT shows a
high proportion of cells positive for hPL and CD146,
and rarely positive for β-hCG or placental alkaline phos-
phatase [8]; it is also immunoreactive for cytokeratins,
epithelial membrane antigen and inhibin-α.
Data regarding genetic analysis of PSTT are quite
limited. Hui et al [9] have analyzed four archived cases
of PSTT by comparative genomic hybridization (CGH).
One case showed chromosomal gains in the regions of
19p13.2, 21q11–21 and 22q12. The second case de-
monstrated a single regional chromosomal gain involv-
ing 21q21. No chromosomal loss was observed. The
remaining two cases showed a balanced CGH profile
without detectable chromosomal gain or loss. In a re-
cent study conducted by the same authors, it was sug-
gested that the development of this tumor might require
a paternally derived X chromosome and the absence of
a Y chromosome as they observed. The presence of an
X chromosome and the absence of a Y chromosome
were observed in all the 20 cases they studied [9].
The differential diagnosis of PSTT includes exagger-
ated placental site, choriocarcinoma, epithelioid tro-
phoblastic tumor (ETT), and epithelioid smooth muscle
tumor. The most difficult differential diagnosis is that
of an exaggerated placental site. Both lesions are char-
acterized by an exuberant infiltration of intermediate
trophoblastic cells in the implantation site. The im-
munophenotype of both lesions is similar. Histologic
features associated with PSTT include confluent masses
of trophoblastic cells, unequivocal mitotic figures, and
the absence of chorionic villi. In addition, exaggerated
placental sites contain larger numbers of multinucleated
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Figure 3. Large pleomorphic polyhedral cells with abundant
eosinophilic cytoplasm, invading the myometrium (hema-
toxylin and eosin stain, 400×).
Figure 4. Hysterectomy specimen revealing a shaggy gray-
white growth protruding from the lower uterine segment.
trophoblastic cells compared with PSTT. In contrast to
the biphasic pattern of choriocarcinoma, PSTT is com-
posed of a monomorphic population of intermediate
trophoblast. The distinctive pattern of vascular inva-
sion and deposition of fibrinoid material are key diag-
nostic features which help in distinguishing PSTT from
ETT. Poorly differentiated carcinoma and metastatic
melanoma can sometimes be confused with PSTT; the
above-described characteristics help in the diagnosis,
as do immunohistochemical stains for hPL, inhibin-α
and HMB-45.
More than half of patients present with disease lim-
ited to the uterus; the remainder present with disease
extension beyond the uterus. The overall mortality rate
is 25%. The most important adverse prognostic factor
is disease extension beyond the uterus. Other adverse
prognostic factors are interval from antecedent preg-
nancy > 2 years, mitotic count > 5 mitotic figures/
10 high-power fields, and age > 40 years. Since PSTT is
less sensitive to chemotherapy than GTDs originating
from cytotrophoblasts and syncytiotrophoblasts (hyda-
tidiform mole, invasive mole, and choriocarcinoma), hys-
terectomy is the mainstay of treatment [10]. The most
common metastatic sites are lungs, liver and vagina
[11]. Systemic multi-agent chemotherapy is administered
in the presence of disease extension beyond the uterus
and is considered in the presence of other adverse prog-
nostic factors. The EP/EMA (chemotherapy with etopo-
side, methotrexate, actinomycin, and cisplatinum)
regimen seems to be the most effective chemotherapy
available to date for PSTT [10].
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